ArticleCureus2026
Intravitreal Adalimumab in Retinitis Pigmentosa: A Prospective Pilot Study Assessing Ocular Safety and Feasibility.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The objective of this study was to evaluate the short-term ocular safety, feasibility, and exploratory functional signals associated with intravitreal adalimumab (ADA) in patients with retinitis pigmentosa (RP). Methods This prospective, single-arm pilot study included 21 patients with RP who received intravitreal adalimumab (2 mg/0.05 mL) at baseline, month 2, and month 4, with follow-up to month 6. The primary objective was to assess ocular safety and treatment feasibility. Exploratory functional outcomes included best-corrected visual acuity (BCVA, logarithm of the minimum angle of resolution (LogMAR)) and automated perimetry parameters (mean deviation (MD), pattern standard deviation (PSD), and Field Preservation Deviation Index (FPDI)). Structural assessment was performed using optical coherence tomography (OCT). Analyses compared baseline and month 6 outcomes using paired statistical methods. BCVA values were analyzed at the patient level as the mean of both eyes. Results All scheduled intravitreal injections were successfully completed, and no serious ocular adverse events were observed during follow-up. Mean BCVA showed no statistically significant change from baseline to month 6 (0.76 to 0.70 LogMAR; p = 0.115). Visual field parameters (MD, PSD, and FPDI) remained stable, with no statistically significant differences over time. OCT findings demonstrated advanced baseline structural alterations consistent with RP, without evidence of treatment-related anatomical deterioration or cystoid macular edema during follow-up. Flicker electroretinography (ERG) responses were measurable in a limited subset of patients and were analyzed descriptively, showing no consistent evidence of decline. Conclusions In this prospective pilot study, intravitreal adalimumab demonstrated a favorable short-term ocular safety profile and was feasible to administer in patients with retinitis pigmentosa. No significant functional or structural changes were observed over six months. These findings are hypothesis-generating and support the need for controlled studies to further evaluate the safety and potential role of tumor necrosis factor alpha (TNF-α) inhibition in inherited retinal degeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.